Companies Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals (CRNX): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Crinetics Pharmaceuticals, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$11,628,959CEO R. Scott Struthers · source

Say-on-pay support97.14%Latest vote · source

CEO vs. named peers33rd pct.Of 12 peer CEOs

CEO pay ratio36:1To the median employee · source

CEO pay, last three years

$5,747,994FY2023
$10,533,579FY2024
$11,628,959FY2025

CEO total pay was $11,628,959 in fiscal 2025, up from $10,533,579 in fiscal 2024.

FY2025: salary $718,500 · bonus $0 · stock awards $3,280,540 · option awards $7,160,564

Executives and directors

R. Scott Struthers · CEO Jeff Knight · COO Marc Wilson · CFO Stephen Betz · Chief Scientific Officer Tobin Schilke · CFO Dana Pizzuti · Executive Camille Bedrosian, M.D · Independent Director Caren Deardorf · Independent Director Matthew K. Fust · Independent Director Rogério Vivaldi Coelho, M.D · Independent Director Stephanie S. Okey, M.S · Independent Director Wendell Wierenga, Ph.D · Chair of the Board Weston Nichols, Ph.D · Independent Director

Frequently asked questions

Who was the highest-paid executive at Crinetics Pharmaceuticals, Inc. in fiscal 2025?

As disclosed, R. Scott Struthers (President, Chief Executive Officer and Director) was the highest-paid executive at Crinetics Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $11,628,959.

How does Crinetics Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?

As disclosed, R. Scott Struthers's total compensation ranked at the 33rd percentile of Crinetics Pharmaceuticals, Inc.'s disclosed peer group.

What is Crinetics Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio?

As disclosed, Crinetics Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio was 36:1.

How did shareholders vote on Crinetics Pharmaceuticals, Inc.'s executive compensation?

As disclosed, 97.14% of shareholders supported Crinetics Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.

How much does Crinetics Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?

As disclosed, Crinetics Pharmaceuticals, Inc. reported total board compensation of $2,097,191 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
R. Scott Struthers	$718,500	$0	$3,280,540	$7,160,564	$462,355	$0	$7,000	$11,628,959
President, Chief Executive Officer and Director
Tobin Schilke	452,250	0	1,755,000	1,670,920	206,056	0	273,667	4,357,893
Chief Financial Officer
Dana Pizzuti	573,333	0	1,584,980	1,487,018	258,000	0	7,000	3,910,331
Chief Medical and Development Officer
Stephen Betz	520,000	0	1,584,980	1,487,018	228,150	0	7,000	3,827,148
Chief Scientific Officer
Jeff Knight	511,667	0	1,584,980	1,487,018	236,006	0	7,000	3,826,671
Chief Operating Officer
Marc Wilson	119,788	0	514,620	2,556,937	0	0	64,047	3,255,392
Former Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
R. Scott Struthers	$11,628,959	$10,533,579	$5,747,994	↑ +1,095,380
Tobin Schilke	4,357,893	—	—	—
Dana Pizzuti	3,910,331	4,209,728	1,102,038	↓ −299,397
Stephen Betz	3,827,148	4,123,937	2,496,868	↓ −296,789
Jeff Knight	3,826,671	4,122,990	2,362,362	↓ −296,319
Marc Wilson	3,255,392	4,434,895	2,513,495	↓ −1,179,503

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

To attract, engage and retain an executive team who will provide leadership for our future success by providing competitive total pay opportunities. To establish a direct link between our business results, individual executive performance and total executive compensation. To align the interests of our executive officers with those of our shareholders.

CEO STI target (% of salary)	65%
CEO LTI target (% of salary)	—
Independent consultant	Pearl Meyer
Clawback policy	True
Anti-hedging	True
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Stephen Betz	RSU	2025-02-20	—	—	43,000	—	$1,584,980
Tobin Schilke	OPTION	2025-03-10	—	—	80,000	—	1,670,920
Jeff Knight	RSU	2025-02-20	—	—	43,000	—	1,584,980
Jeff Knight	OPTION	2025-02-20	—	—	65,000	—	1,487,018
Dana Pizzuti	OPTION	2025-02-20	—	—	65,000	—	1,487,018
R. Scott Struthers	OPTION	2025-02-20	—	—	313,000	—	7,160,564
Tobin Schilke	RSU	2025-03-10	—	—	52,000	—	1,755,000
R. Scott Struthers	RSU	2025-02-20	—	—	89,000	—	3,280,540
Dana Pizzuti	RSU	2025-02-20	—	—	43,000	—	1,584,980
Stephen Betz	OPTION	2025-02-20	—	—	65,000	—	1,487,018

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Stephen Betz	$1,584,980	$0	$1,487,018	0.0%
Tobin Schilke	1,755,000	0	1,670,920	0.0%
Jeff Knight	1,584,980	0	1,487,018	0.0%
Dana Pizzuti	1,584,980	0	1,487,018	0.0%
R. Scott Struthers	3,280,540	0	7,160,564	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Jeff Knight	Option	963	20.02	—
Jeff Knight	RSU	1,238	—	57,629
Dana Pizzuti	RSU	2,250	—	104,738
Stephen Betz	Option	3,209	20.02	—
Marc Wilson	Option	3,792	20.02	—
Stephen Betz	RSU	4,125	—	192,019
Marc Wilson	RSU	4,875	—	226,931
Dana Pizzuti	Option	6,563	19.64	—
R. Scott Struthers	Option	10,384	20.02	—
Stephen Betz	RSU	11,800	—	549,290
Marc Wilson	RSU	12,100	—	563,255
R. Scott Struthers	RSU	13,350	—	621,443
Jeff Knight	RSU	14,750	—	686,613
Dana Pizzuti	RSU	17,250	—	802,988
Stephen Betz	RSU	17,250	—	802,988
Jeff Knight	RSU	17,250	—	802,988
Marc Wilson	RSU	19,125	—	890,269
Jeff Knight	Option	28,438	19.64	—
R. Scott Struthers	RSU	30,826	—	1,434,950
Stephen Betz	Option	34,375	19.64	—
Marc Wilson	Option	35,266	19.64	—
Dana Pizzuti	RSU	43,000	—	2,001,650
Stephen Betz	RSU	43,000	—	2,001,650
Jeff Knight	RSU	43,000	—	2,001,650
Dana Pizzuti	Option	43,125	16.89	—
R. Scott Struthers	RSU	48,750	—	2,269,313
Dana Pizzuti	Option	48,938	43.51	—
Stephen Betz	Option	48,938	43.51	—
Jeff Knight	Option	48,938	43.51	—
Dana Pizzuti	Option	51,459	36.86	—
Stephen Betz	Option	51,459	36.86	—
Jeff Knight	Option	51,459	36.86	—
Tobin Schilke	RSU	52,000	—	2,420,600
Marc Wilson	Option	53,719	43.51	—
Tobin Schilke	Option	80,000	33.75	—
R. Scott Struthers	RSU	89,000	—	4,142,950
R. Scott Struthers	Option	89,907	19.64	—
R. Scott Struthers	Option	135,000	43.51	—
R. Scott Struthers	Option	247,792	36.86	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Wendell Wierenga, Ph.DIndependent · Board Chair · Nominating/Governance (Chair) · Compensation · Research and Development	$103,025	$223,077	$202,515	$0	$0	$528,617
Rogério Vivaldi Coelho, M.DIndependent · Audit · Research and Development · Global Therapeutics Strategy and Access (Chair)	81,750	223,077	202,515	0	0	507,342
Stephanie S. Okey, M.SIndependent · Compensation (Chair) · Nominating/Governance · Global Therapeutics Strategy and Access	74,875	223,077	202,515	0	0	500,467
Camille Bedrosian, M.DIndependent · Research and Development (Chair) · Nominating/Governance · Global Therapeutics Strategy and Access	74,875	223,077	202,515	0	0	500,467
Matthew K. FustIndependent · Audit (Chair) · Compensation	73,000	223,077	202,515	0	0	498,592
Weston Nichols, Ph.DIndependent · Audit · Research and Development	68,252	223,077	202,515	0	0	493,844
Caren DeardorfIndependent · Nominating/Governance · Global Therapeutics Strategy and Access	59,875	223,077	202,515	0	0	485,467
R. Scott Struthers, Ph.DEmployee director	0	0	0	—	0	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$520,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 15,000 / 10,000
Stock ownership guideline	3x annual cash retainer

Total cost of the board

Component	FY2025
Cash retainers and fees	$535,652
Equity awards (grant-date value)	$1,561,539
All other compensation	$0
Total cost of the board	$2,097,191

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Crinetics Pharmaceuticals as a peer

Companies that benchmark against CRNX

23 companies name CRNX as a compensation peer

AGIOS PHARMACEUTICALS, INC.AGIOFY2025
Akero Therapeutics, Inc.AKROFY2024
ARVINAS, INC.ARVNFY2025
Atrium Therapeutics, Inc.RNAFY2024
Avidity Biosciences, Inc.RNAMFY2024
Biohaven Ltd.BHVNFY2025
CYTOKINETICS INCCYTKFY2025
Dyne Therapeutics, Inc.DYNFY2025
IDEAYA Biosciences, Inc.IDYAFY2025
IOVANCE BIOTHERAPEUTICS, INC.IOVAFY2025
Janux Therapeutics, Inc.JANXFY2025
Keros Therapeutics, Inc.KROSFY2025
Kura Oncology, Inc.KURAFY2025
Merus N.V.MRUSFY2024
Mirum Pharmaceuticals, Inc.MIRMFY2025
NOVAVAX INCNVAXFY2025
PLIANT THERAPEUTICS, INC.PLRXFY2025
Protagonist Therapeutics, IncPTGXFY2025
Scholar Rock Holding CorpSRRKFY2025
Vera Therapeutics, Inc.VERAFY2025
Viking Therapeutics, Inc.VKTXFY2025
Viridian Therapeutics, Inc.\DEVRDNFY2025

Each company listed discloses CRNX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRNX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

AGIO Agios Pharmaceuticals, Inc.MDGL Madrigal PharmaceuticalsBBIO BridgeBio Pharma, Inc.RYTM Rhythm Pharmaceuticals, Inc.DNLI Denali Therapeutics Inc.TGTX TG Therapeutics, IncRNAM Avidity BiosciencesSWTX SpringWorks TherapeuticsIOVA Iovance Biotherapeutics, Inc.ARWR Arrowhead Pharmaceuticals, Inc.IBRX ImmunityBio, Inc.SMMT Summit Therapeutics Inc

Peer reciprocity

The companies Crinetics Pharmaceuticals, Inc. names as compensation peers that name it back in their own disclosed peer groups.

Agios Pharmaceuticals, Inc. (AGIO)¹⁸⁷Avidity Biosciences (RNAM)¹⁸⁸Iovance Biotherapeutics, Inc. (IOVA)¹⁸⁹

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Summit Therapeutics Inc	2025	Mahkam Zanganeh	$616,500	$0	$245,021,384	$0	$246,047,279
2	TG Therapeutics, Inc	2025	Michael Weiss	875,000	23,550,000	0	1,146,250	25,571,250
3	Madrigal Pharmaceuticals	2025	Bill Sibold	918,531	12,297,850	4,537,146	1,438,814	19,206,341
4	Rhythm Pharmaceuticals, Inc.	2025	David Meeker	807,692	8,274,785	7,688,560	759,488	17,544,525
5	SpringWorks Therapeutics	2024	Saqib Islam	760,000	7,899,760	6,689,100	798,000	16,153,317
6	BridgeBio Pharma, Inc.	2025	Neil Kumar	1,044,000	10,606,275	1,874,992	0	14,944,585
7	Avidity Biosciences	2024	Sarah Boyce	659,900	10,748,480	2,157,090	594,000	14,176,480
8	ImmunityBio, Inc.	2025	Richard Adcock	831,667	2,787,828	8,353,406	485,166	12,716,953
9	Crinetics Pharmaceuticals, Inc.	2025	R. Scott Struthers	718,500	3,280,540	7,160,564	462,355	11,628,959
10	Arrowhead Pharmaceuticals, Inc.	2025	Christopher Anzalone	981,046	6,810,292	0	1,236,000	9,029,861
11	Agios Pharmaceuticals, Inc.	2025	Brian Goff	846,864	1,291,680	2,627,252	592,804	5,370,389
12	Denali Therapeutics Inc.	2025	Ryan Watts	718,000	1,151,867	2,180,003	0	4,751,515
13	Iovance Biotherapeutics, Inc.	2025	Frederick Vogt	800,000	759,375	0	312,000	1,888,175

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Crinetics Pharmaceuticals, Inc.	not disclosed	Options 70 · RSU 30	not disclosed	Pearl Meyer
Agios Pharmaceuticals, Inc.	100%	Option 40 · PSU 40 · RSU 20	No	Aon
Arrowhead Pharmaceuticals, Inc.	125%	PRSU 70 · RSU 30	not disclosed	Compensia
Avidity Biosciences	not disclosed	Option 80 · RSU 20	not disclosed	Alpine Rewards, LLC
BridgeBio Pharma, Inc.	135%	RSU 50 · PSU 35 · Options 15	No	Aon Talent Solutions
Denali Therapeutics Inc.	145%	not disclosed	not disclosed	Alpine Rewards
ImmunityBio, Inc.	not disclosed	Option 75 · RSU 25	not disclosed	Mercer
Iovance Biotherapeutics, Inc.	60%	not disclosed	No	Haigh & Company
Madrigal Pharmaceuticals	not disclosed	PSU 33.33 · RSU 33.33 · Option 33.33	Yes — Relative TSR vs Nasdaq Biotechnology Index	Compensia, Inc.
Rhythm Pharmaceuticals, Inc.	120%	Options 50 · RSU 50	No	Pay Governance
SpringWorks Therapeutics	140%	not disclosed	Yes — Relative Total Shareholder Return (TSR)	Aon
Summit Therapeutics Inc	105%	Options 100	not disclosed	not disclosed
TG Therapeutics, Inc	131%	RSU 100	No	Compensia, Inc.

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-18	91,657,992	2,698,538	2,629,874	97.14%	Passed
2025	2025-06-11	82,658,715	2,636,436	20,915	96.91%	Passed
2024	2024-06-07	64,052,127	1,745,589	6,019	97.35%	Passed
2023	2023-06-16	45,092,585	1,192,212	2,997	97.42%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-18	97.14%^a
2025	2025-06-11	96.91%^b
2024	2024-06-07	97.35%^c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	36 : 1
CEO total compensation	$11,628,959
Median employee compensation	$325,071

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
R. Scott Struthers	Director	2026-05-29	D	111,100	$0	$0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	D	111,100	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	80,000	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	222,200	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	D	80,000	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	D	222,200	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	222,200	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	111,100	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	D	222,200	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	111,100	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	D	111,100	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	D	111,100	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	111,100	0	0	Common, indirect	Form 4 ↗
R. Scott Struthers	Director	2026-05-29	A	111,100	0	0	Common, indirect	Form 4 ↗
Stephanie Okey	Director	2026-06-17	D	6,292	36	224,121	Common, open-market sale	Form 4 ↗
Stephanie Okey	Director	2026-06-17	D	608	36	22,022	Common, open-market sale	Form 4 ↗
Stephanie Okey	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Wendell Wierenga	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Matthew K. Fust	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Matthew K. Fust	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Wendell Wierenga	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Weston Nichols	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Caren Deardorf	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-06-18	A	9,730	0	0	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Caren Deardorf	Director	2026-06-18	A	5,925	0	0	Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-07-02	D	3,000	40	120,000	Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	A	4,995	20	100,000	Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	A	6,542	15	100,027	Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	D	4,995	0	0	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	D	6,542	0	0	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	D	4,422	0	0	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	D	3,969	0	0	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	A	4,422	23	99,981	Common	Form 4 ↗
R. Scott Struthers	Director	2026-08-07	A	3,969	25	99,979	Common	Form 4 ↗
Tobin Schilke	Chief Financial & Infra. Ofcr.	2026-08-20	A	471	0	0	Common	Form 4 ↗
Tobin Schilke	Chief Financial & Infra. Ofcr.	2026-09-01	D	71,471	85	6,075,035	Common	Form 4 ↗
Tobin Schilke	Chief Financial & Infra. Ofcr.	2026-09-01	D	7,956	85	676,260	Common	Form 4 ↗
Isabel Kalofonos	Chief Commercial Officer	2026-09-01	D	34,000	85	2,890,000	Common	Form 4 ↗
Isabel Kalofonos	Chief Commercial Officer	2026-09-01	D	1,669	85	141,865	Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	17,500	65	1,133,475	Derivative, Class A Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	35,000	66	2,299,500	Derivative, Class A Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	22,836	85	1,941,060	Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	16,300	85	1,385,500	Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	12,500	62	772,000	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	16,300	85	1,385,500	Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	15,000	62	927,150	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	25,000	69	1,723,000	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	17,500	67	1,167,425	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	17,500	65	1,133,475	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	87,000	41	3,609,630	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	259,058	70	18,058,933	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	111,100	85	9,443,500	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	110,000	85	9,350,000	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	106,000	85	9,010,000	Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	65,000	48	3,129,100	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	74,540	76	5,644,169	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	35,000	57	1,984,150	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	287,700	65	18,804,072	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	244,205	65	15,868,441	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	172,281	60	10,304,127	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	176,663	85	15,016,355	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	111,100	85	9,443,500	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	100,000	85	8,500,000	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	248,043	85	21,083,655	Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	47,000	41	1,936,870	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	56,250	60	3,364,313	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	17,500	65	1,133,475	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	6,400	85	544,000	Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	2,092	83	173,824	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	17,500	65	1,133,475	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	12,500	62	772,125	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	25,000	61	1,521,250	Derivative, Class A Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	110,000	65	7,189,600	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	60,000	62	3,743,400	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	90,514	83	7,520,808	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	79,650	85	6,770,250	Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	58,286	85	4,954,310	Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Tobin Schilke	Chief Financial & Infra. Ofcr.	2026-09-01	D	50,000	41	2,060,500	Derivative, Class A Common	Form 4 ↗
Isabel Kalofonos	Chief Commercial Officer	2026-09-01	D	55,000	41	2,266,550	Derivative, Class A Common	Form 4 ↗
Isabel Kalofonos	Chief Commercial Officer	2026-09-01	D	97,500	44	4,329,975	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	116,146	85	9,872,410	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	313,000	48	15,067,820	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	80,000	85	6,800,000	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	1,000	85	85,000	Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	17,500	67	1,167,425	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	12,500	62	772,000	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	17,500	67	1,167,425	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	4,375	67	291,856	Derivative, Class A Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	5,925	85	503,625	Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	8,750	67	583,713	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	12,500	40	503,625	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	17,500	65	1,131,900	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Wendell Wierenga	Director	2026-09-01	D	12,500	62	772,125	Derivative, Class A Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	16,300	85	1,385,500	Common	Form 4 ↗
Matthew K. Fust	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
Stephanie Okey	Director	2026-09-01	D	12,500	62	772,125	Derivative, Class A Common	Form 4 ↗
Coelho Rogerio Vivaldi	Director	2026-09-01	D	13,300	85	1,130,500	Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	240,000	41	9,957,600	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	195,578	62	12,202,111	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	111,100	85	9,443,500	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	111,100	85	9,443,500	Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	136,805	85	11,628,425	Common	Form 4 ↗
Tobin Schilke	Chief Financial & Infra. Ofcr.	2026-09-01	D	80,000	51	4,100,000	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	77,000	65	5,003,460	Derivative, Class A Common	Form 4 ↗
Stephen Betz	Chief Scientific Officer	2026-09-01	D	85,000	70	5,925,350	Derivative, Class A Common	Form 4 ↗
Camille L. Bedrosian	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Caren Deardorf	Director	2026-09-01	D	9,730	49	478,035	Derivative, Class A Common	Form 4 ↗
Weston Nichols	Director	2026-09-01	D	10,350	53	545,135	Derivative, Class A Common	Form 4 ↗
R. Scott Struthers	Director	2026-09-01	D	228,000	41	9,395,880	Derivative, Class A Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (189 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, R. Scott Struthers. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 43. As printed: 11,628,959. View filing ↗
Section 01, Tobin Schilke. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 4,357,893. View filing ↗
Section 01, Dana Pizzuti. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 3,910,331. View filing ↗
Section 01, Stephen Betz. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 3,827,148. View filing ↗
Section 01, Jeff Knight. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 3,826,671. View filing ↗
Section 01, Marc Wilson. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 3,255,392. View filing ↗
Section 03, Stephen Betz RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tobin Schilke OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeff Knight RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeff Knight OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Dana Pizzuti OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, R. Scott Struthers OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tobin Schilke RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, R. Scott Struthers RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Dana Pizzuti RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Stephen Betz OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-29. Section “CEO Pay Ratio”. As printed: 36 : 1. View filing ↗
Section 08, Wendell Wierenga, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 528,617. View filing ↗
Section 08, Rogério Vivaldi Coelho, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 507,342. View filing ↗
Section 08, Stephanie S. Okey, M.S. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 500,467. View filing ↗
Section 08, Camille Bedrosian, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 500,467. View filing ↗
Section 08, Matthew K. Fust. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 498,592. View filing ↗
Section 08, Weston Nichols, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 493,844. View filing ↗
Section 08, Caren Deardorf. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 485,467. View filing ↗
Section 08, R. Scott Struthers, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tobin Schilke 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tobin Schilke 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tobin Schilke 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Isabel Kalofonos 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Isabel Kalofonos 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tobin Schilke 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Isabel Kalofonos 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Isabel Kalofonos 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Wendell Wierenga 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew K. Fust 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephanie Okey 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Coelho Rogerio Vivaldi 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tobin Schilke 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Betz 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Camille L. Bedrosian 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Caren Deardorf 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Weston Nichols 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, R. Scott Struthers 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-22. Item 5.07 · say-on-pay result. As reported: 97.14% (votes for as printed: 91,657,992). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 96.91% (votes for as printed: 82,658,715). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-10. Item 5.07 · say-on-pay result. As reported: 97.35% (votes for as printed: 64,052,127). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 535,652 + equity 1,561,539 + all other 0 = 2,097,191, summed across the director compensation table rows.
Summit Therapeutics Inc, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Summit Therapeutics Inc's own proxy. As printed: 246,047,279. View filing ↗
TG Therapeutics, Inc, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics, Inc's own proxy. As printed: 25,571,250. View filing ↗
Madrigal Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. View filing ↗
Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
SpringWorks Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. View filing ↗
BridgeBio Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. View filing ↗
Avidity Biosciences, Section 10b CEO total. DEF 14A. CEO total compensation as printed in Avidity Biosciences's own proxy. As printed: 14,176,480. View filing ↗
ImmunityBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. View filing ↗
Crinetics Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
Iovance Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. View filing ↗
Section 10a, Agios Pharmaceuticals, Inc. reciprocity. DEF 14A. Agios Pharmaceuticals, Inc. names Crinetics Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Avidity Biosciences reciprocity. DEF 14A. Avidity Biosciences names Crinetics Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Iovance Biotherapeutics, Inc. reciprocity. DEF 14A. Iovance Biotherapeutics, Inc. names Crinetics Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗